LY2181308
LY2181308 is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]
It being investigated for a number of different cancers.[2]
It is targeted at survivin which prevents cells dying.[3]
Clinical trials[edit | edit source]
It has completed a phase II trial for acute myeloid leukemia.[4]
A phase II trial for non-small cell lung cancer has started.[5]
A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]
References[edit | edit source]
- ↑
- ↑ "Search of: LY2181308". ClinicalTrials.gov.
- ↑ "Cancer". Isis Pharmaceuticals. Archived from the original on 2009-10-10. Retrieved 2019-08-31.
{{cite web}}: Unknown parameter|dead-url=ignored (help) - ↑ "A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia". ClinicalTrials.gov.
- ↑ "Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer". ClinicalTrials.gov.
- ↑ "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer". ClinicalTrials.gov.
| LY2181308 Resources | ||
|---|---|---|
|
| |
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
